Larynx Cancer Drug Pipeline Analysis Report 2025
Description
According to the American Cancer Society, larynx cancer is expected to affect 12,650 individuals in the United States in 2024. Out of this, 10,030 are men and 2,620 are women. Most people are diagnosed with larynx cancer at the age of 55 and above. Currently, several clinical trials are ongoing to develop effective and efficient larynx cancer therapeutics to manage the condition including chemoradiation therapy, and neoadjuvant chemotherapy among others.
Report Coverage
The Larynx Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights into larynx cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for larynx cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include larynx cancer analytical perspective based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from larynx cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing larynx cancer pipeline development activities are covered in the report.
Larynx Cancer Drug Pipeline Outlook
Laryngeal cancer affects the larynx (a part of the throat). It helps a person speak, breathe, and swallow and contains the vocal cords. Larynx cancer can be formed in one of the three main areas of the larynx, including, supraglottis, glottis, and subglottis. Approximately 1 in 3 laryngeal cancers, i.e., 35%, starts in supraglottis part. Additionally, more than half of laryngeal cancers, i.e., 60%, start in the glottis part and approximately 5% of laryngeal cancers (1 in 20) starts in subglottis region. It can be caused by some forms of human papillomavirus, a sexually transmitted infection can cause larynx cancer.
The symptoms of larynx cancer at an initial level can be mistaken as a sign of a cold. Other symptoms include sore throat or cough, lump in neck or throat, pain while swallowing, ear pain and voice change, among others. There are two stages of larynx cancer, including, early laryngeal cancer and advanced laryngeal cancer. In stages 0, 1 and 2, the tumor size is small, and cancer doesn’t spread beyond the larynx. In stages 3 and 4, the tumor size is large and affects vocal cords or invades other areas of the body which is considered advanced laryngeal cancer.
Larynx cancer therapeutic drugs include radiation therapy, chemotherapy, immunotherapy, and targeted therapy among others. In chemotherapy, oncologists use medications to kill or slow down the cancer cells' growth. It is given intravenously. In immunotherapy, the treatment uses the patient’s immune system, and the body’s natural defenses to fight cancer. It is also called biologic therapy. While in targeted therapy, the treatment targets cancer cells with specific types of proteins and prevents cell multiplication. The clinical trials for larynx cancer focus on the development of larynx cancer emerging drugs and improving the existing ones. The University of Michigan Rogel Cancer Center is currently conducting phase II trials for several drugs, namely, Cisplatin, and Cetuximab. This trial is expected to help in identifying how many patients are responding to chemotherapy plus radiation therapy to reduce the number of patients who require surgery for larynx cancer. Several companies and institutes are also developing treatments to manage the condition.
Larynx Cancer – Drug Pipeline Therapeutic Assessment
This section of the larynx cancer report covers the analysis of larynx cancer drugs based on several segmentations including:
By Phase
The larynx cancer report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for larynx cancer.
Larynx Cancer – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under larynx cancer pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The targeted drugs given for laryngeal cancer include cetuximab, embrolizumab among others. Monoclonal antibodies are proteins which are made in laboratories which act like proteins called antibodies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for larynx cancer.
Larynx Cancer Clinical Trials Assessment – Competitive Dynamics
The EMR report for the larynx cancer drug pipeline covers the profile of key companies involved in clinical trials and larynx cancer commercial assessment of products. Below is the list of a few players involved in larynx cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and larynx cancer therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming larynx cancer drug candidates.
Drug: DOCETAXEL
The trial is designed to compare two regimen of chemotherapy which are being used as first treatment for patients having tumors that would be treated with total laryngectomy. The trial is sponsored by Groupe Oncologie Radiotherapie Tete et Cou and is currently under phase III.
Drug: Pemetrexed
The objective of the study is to estimate progression free survival in patients with metastatic head and neck cancer not received chemotherapy in this setting. The trial is sponsored by Eli Lilly and Company and is currently under phase II.
Reasons To Buy This Report
The Larynx Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for larynx cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within larynx cancer pipeline insights.
Key Questions Answered in the Larynx Cancer – Pipeline Assessment Report
Laryngeal Cancer Therapeutics Market
Global Cancer Supportive Care Drugs Market
Global Cancer Therapeutics Market
Report Coverage
The Larynx Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights into larynx cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for larynx cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include larynx cancer analytical perspective based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from larynx cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing larynx cancer pipeline development activities are covered in the report.
Larynx Cancer Drug Pipeline Outlook
Laryngeal cancer affects the larynx (a part of the throat). It helps a person speak, breathe, and swallow and contains the vocal cords. Larynx cancer can be formed in one of the three main areas of the larynx, including, supraglottis, glottis, and subglottis. Approximately 1 in 3 laryngeal cancers, i.e., 35%, starts in supraglottis part. Additionally, more than half of laryngeal cancers, i.e., 60%, start in the glottis part and approximately 5% of laryngeal cancers (1 in 20) starts in subglottis region. It can be caused by some forms of human papillomavirus, a sexually transmitted infection can cause larynx cancer.
The symptoms of larynx cancer at an initial level can be mistaken as a sign of a cold. Other symptoms include sore throat or cough, lump in neck or throat, pain while swallowing, ear pain and voice change, among others. There are two stages of larynx cancer, including, early laryngeal cancer and advanced laryngeal cancer. In stages 0, 1 and 2, the tumor size is small, and cancer doesn’t spread beyond the larynx. In stages 3 and 4, the tumor size is large and affects vocal cords or invades other areas of the body which is considered advanced laryngeal cancer.
Larynx cancer therapeutic drugs include radiation therapy, chemotherapy, immunotherapy, and targeted therapy among others. In chemotherapy, oncologists use medications to kill or slow down the cancer cells' growth. It is given intravenously. In immunotherapy, the treatment uses the patient’s immune system, and the body’s natural defenses to fight cancer. It is also called biologic therapy. While in targeted therapy, the treatment targets cancer cells with specific types of proteins and prevents cell multiplication. The clinical trials for larynx cancer focus on the development of larynx cancer emerging drugs and improving the existing ones. The University of Michigan Rogel Cancer Center is currently conducting phase II trials for several drugs, namely, Cisplatin, and Cetuximab. This trial is expected to help in identifying how many patients are responding to chemotherapy plus radiation therapy to reduce the number of patients who require surgery for larynx cancer. Several companies and institutes are also developing treatments to manage the condition.
Larynx Cancer – Drug Pipeline Therapeutic Assessment
This section of the larynx cancer report covers the analysis of larynx cancer drugs based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Peptides
- Recombinant Proteins
- Small Molecule
- Oral
- Parenteral
- Others
The larynx cancer report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for larynx cancer.
Larynx Cancer – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under larynx cancer pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The targeted drugs given for laryngeal cancer include cetuximab, embrolizumab among others. Monoclonal antibodies are proteins which are made in laboratories which act like proteins called antibodies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for larynx cancer.
Larynx Cancer Clinical Trials Assessment – Competitive Dynamics
The EMR report for the larynx cancer drug pipeline covers the profile of key companies involved in clinical trials and larynx cancer commercial assessment of products. Below is the list of a few players involved in larynx cancer clinical trials:
- Groupe Oncologie Radiotherapie Tete et Cou
- Travera Inc.
- Eli Lilly and Company
- Klus Pharma Inc.
- INSYS Therapeutics Inc.
- Rapa Therapeutics LLC
- Daiichi Sankyo
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and larynx cancer therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming larynx cancer drug candidates.
Drug: DOCETAXEL
The trial is designed to compare two regimen of chemotherapy which are being used as first treatment for patients having tumors that would be treated with total laryngectomy. The trial is sponsored by Groupe Oncologie Radiotherapie Tete et Cou and is currently under phase III.
Drug: Pemetrexed
The objective of the study is to estimate progression free survival in patients with metastatic head and neck cancer not received chemotherapy in this setting. The trial is sponsored by Eli Lilly and Company and is currently under phase II.
Reasons To Buy This Report
The Larynx Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for larynx cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within larynx cancer pipeline insights.
Key Questions Answered in the Larynx Cancer – Pipeline Assessment Report
- What is the current landscape of larynx cancer disease pipeline drugs?
- Which companies/institutions are developing larynx cancer disease emerging drugs?
- How many phase II drugs are currently present in larynx cancer disease pipeline drugs?
- Which company is leading the larynx cancer disease pipeline development activities?
- What is the current larynx cancer disease therapeutic assessment?
- What are the opportunities and challenges present in the Larynx Cancer disease drug pipeline landscape?
- What is the efficacy and safety profile of larynx cancer disease pipeline drugs?
- Which companies/institutions are involved in larynx cancer disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in larynx cancer disease?
Laryngeal Cancer Therapeutics Market
Global Cancer Supportive Care Drugs Market
Global Cancer Therapeutics Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Larynx Cancer
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Larynx Cancer
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Larynx Cancer
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Larynx Cancer: Epidemiology Snapshot
- 5.1 Larynx Cancer Incidence by Key Markets
- 5.2 Larynx Cancer – Patients Seeking Treatment in Key Markets
- 6 Larynx Cancer: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Larynx Cancer: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Larynx Cancer, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Larynx Cancer Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Larynx Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: DOCETAXEL
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Vemurafenib
- 10.2.3 Drug: cevimeline hydrochloride
- 10.2.4 Other Drugs
- 11 Larynx Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Nivolumab
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Durvalumab
- 11.2.3 Other Drugs
- 12 Larynx Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: AZD1775
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: BKM120
- 12.2.3 Other Drugs
- 13 Larynx Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug: F-18 RGD-K5
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Larynx Cancer, Key Drug Pipeline Companies
- 14.1 Groupe Oncologie Radiotherapie Tete et Cou
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Travera Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Eli Lilly and Company
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Klus Pharma Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 INSYS Therapeutics Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Rapa Therapeutics LLC
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Daiichi Sankyo
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
